June 15, 2021 5:15pm

The Biostage (BSTG) Chronicles: The “pump” did not promote/work, after volume of 10,703 shares pricing DROPPED -$0.039 to $1.21 after Monday’s 2,305 shares traded with NO gain

Pre-open indications: 2 HITs and 4 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

The Dow closed DOWN – 94.42 points (-0.37%); the S&P closed DOWN -8.56 points (-0.20%) while the Nasdaq closed DOWN -101.28 points (-0.71%)

 

Henry’omics:

Indexes fell on Tuesday with the Dow, S&P 500 and the Nasdaq slipped from their record highs, as data showing stronger inflation and weaker U.S. retail sales in May spooked already-jittery investors awaiting the results of the Federal Reserve's latest policy meeting.

  • investors await key Federal Reserve’s monetary policy reporting

 

Data Docket: a mixed bag, as retail sales fall, producer prices Jump … the final demand index for producer prices advanced 6.6% for the 12 months ended in May, the largest increase since 12-month data were first calculated in November 2010. On a monthly basis, the producer price index for final demand rose 0.8%, ahead of the estimate of 0.6%. Producer prices measure the prices paid to producers as opposed to prices on the consumer level.

  • Surprisingly, the varied data hasn’t raised any concerns in the market

 

RegMed Investors’ (RMi) pre-open: “are you ready … for the dropping of many of the sectors pricing elevations – it’s coming, minimize your impact!” … https://www.regmedinvestors.com/articles/11955

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Tuesday opened negative at 8/26 and 1 acquired, stayed negative at the mid-day to 3/29, 2 flats and 1 acquired, closing negative at 5/28, 1 flat and 1 acquired;
  • Monday opened positive at 26/7, 1 flat and 1 acquired, stayed positive at the mid-day to 19/14, 2 flats and 1 acquired, closing positive at 18/14, 2 flats and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump” did not promote, after volume of 10,703 shares, pricing DROPPED to -$0.039 to $1.21 after Monday’s 2,305 shares traded with NO gain … after Friday’s 1,395 shares traded moving up +$0.04 to $1.25, Thursday’s 1,050 share traded only moved the share price +$0.01 to $1.21, Wednesday’s 2,200 shares traded with a negative close of -$0.06 to $1.20, Tuesday’s 1,216 shares traded i.e., were “pumped” as the stock increased +0.13 to $1.26 and last Monday’s 2,350 shares traded dropping the stock -$0.17 to $1.13, WHO is buying this “zombie”?

 

Pre-open Indications: 2 HITs <Biostage (BSTG -$0.039), Sage Therapeutics (SAGE -$14.06)> and 4 MISS < Cellectis SA (CLLS -$0.74), uniQure NV (QURE -$0.43), Verastem (VSTM -$0.06), Global Blood Therapeutics (GBT -$0.73)>  

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • BioLife Solutions (BLFS), Applied Genetic Technologies (AGTC), Intellia Therapeutics (NTLA), Voyager Therapeutics (VYGR), Brainstorm Cell Therapeutics (BCLI) to name 5 of the 5 inclining of the 35 covered

Hammered in today’s market:

  • Sage Therapeutics (SAGE) - again, CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Fate Therapeutics (FATE), Ultragenyx (RARE) to name 5 of the 28 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 2 of the 5-upside having higher than the 3-month average volume with the volume of 9 of 29-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 5-upside were +0.21% (VYGR) to +2.51% (BLFS) while the 28-downside ranges from -0.10% (ALNY) to -19.30% (SAGE);

 

Tuesday’s (5 of 5) incliners:

  • BioLife Solutions (BLFS +$0.97 after Monday’s +$0.63);
  • Intellia Therapeutics (NTLA +$0.65 after Monday’s +$2.71);
  • Applied Genetic Technologies (+$0.21);
  • Brainstorm Cell therapeutics (BCLI +$0.06);
  • Voyager Therapeutics (VYGR +$0.01);

Tuesday’s (10 of 28) decliners:

  • Sage Therapeutics (SAGE -$14.06 after Monday’s +$6.25);
  • CRISPR Therapeutics (CRSP -$5.14 after Monday’s +$3.29);
  • Editas Medicine (EDIT -$3.43 after Monday’s +$1.11);
  • Fate Therapeutics (FATE -$3.18 after Monday’s +$0.22);
  • Ultragenyx (RARE -$2.84 after Monday’s +$1.17);
  • Ionis Pharmaceuticals (IONS -$1.11 after Monday’s -$0.14);
  • Regenxbio (RGNX -$0.96 after Monday’s -$0.16);
  • Cellectis SA (CLLS -$0.74 after Monday’s +$0.62);
  • Global Blood Therapeutics (GBT -$0.73 after Monday’s -$0.36);
  • bluebird bio (BLUE -$0.70 after Monday’s -$0.57);

Closing flat - 1 – ReNeuron (RENE.L) and 1 -Stemline Therapeutics (STML – acquired)

 

COVID-19 updates: might be almost time to drop these stats

More than half of Americans have received at least one dose of a vaccine and 42% are fully vaccinated.

Friday’s COVID Data Tracker <Million>:

  • Cases: 34,342 M 
  • Death rate totaled 615,489 M
  • Recovered/Discharged 28,858,479

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -1.48% and XBI closed down -2.38%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.63 points or +3.84% at 17.02

Upside volume: weak

  • Tuesday: 2 out of the 5-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 9 out of the 28-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Tuesday’s percentage (%) of the 5-upside were +0.21% (VYGR) to +2.51% (BLFS) while the 28-downside ranges from –0.10% (ALNY) to -19.30% (SAGE);

 

June, third month of Q2/21:

Tuesday closed negative with 5 advancers, 28 decliners, 1 flat and 1 acquired

Monday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE: The decline HAD to HAPPEN after eight (8) of ten (10) positive sector closes in June … that includes seven (7) in a row

it's still a tricky market, don’t be ‘suckered” by the new of newest highs.

I’m in for the “ride” however, I’m STIL expecting the sector rotation trades to continue to play out – I’m maintaining SELLING into STRENGTH into Friday.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.